The U.S. Food and Drug Administration has approved Dechra Veterinary Products’ Vetoryl (trilostane) Capsules. The product is intended for treating pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing’s syndrome in dogs. Vetoryl also has received the designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors, the first drug to receive approval for this indication and the first drug to receive a Minor Use designation in dogs, according to the company. Dechra is based in Overland Park, Kan. <HOME>
